Chromadex Corp. (CDXC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152305,
    "name": "Chromadex Corp.",
    "stock_name": "Chromadex Corp.",
    "full_name": "Chromadex Corp.",
    "name_url": "stocks-analysis/chromadex-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.70",
    "chg": 0.3,
    "chgp": "4.69%",
    "dir": 1,
    "prev_price": "6.40",
    "mcapval": "753.67",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2310,
    "indexname": "S&P 500",
    "isin": "US1710774076",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.16 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/chromadex-corp-1152305-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Chromadex Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/chromadex-corp-forms-death-cross-signaling-potential-bearish-trend-ahead-3658973",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ChromadexCorp_dealthcross_3658973.png",
        "date": "2025-10-30 15:33:16",
        "description": "Chromadex Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has performed well over the past year, recent trends show a decline. Mixed technical indicators suggest varying momentum, prompting investor attention on the company's market position."
      },
      {
        "title": "Is Chromadex Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-chromadex-corp-overvalued-or-undervalued-3637960",
        "imagepath": "",
        "date": "2025-10-21 12:12:27",
        "description": "As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company appears to be undervalued, particularly given its impressive PEG ratio of 0.07, which suggests significant growth potential relative to its price, alongside a high ROCE of 1532.90% and a ROE of 29.28%. \n\nIn comparison to peers, Chromadex Corp. has a P/E ratio of 63, which is notably higher than LifeVantage Corp.'s attractive P/E of 14.81, yet lower than USANA Health Sciences' expensive P/E of 16.23. Despite recent short-term underperformance, with a 1-month return of -23.88% compared to the S&P 500's 0.96%, the company has shown remarkable long-term performance, with a 1-year return of 113.08% versus the S&P 500's 14.08%. This long-term outperformance reinforces the attractiveness of Chromadex Corp.'s current valuation...."
      },
      {
        "title": "Chromadex Corp. Experiences Valuation Adjustment Amid Strong Financial Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/chromadex-corp-sees-valuation-grade-shift-from-expensive-to-attractive-amid-strong-stock-performance-3640576",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ChromadexCorp_valuationdot_3640576.png",
        "date": "2025-10-20 15:46:37",
        "description": "Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has a notably high P/E ratio of 63 and a Price to Book Value of 18.43. Despite elevated valuation metrics, the company demonstrates strong operational efficiency with a ROCE of 1532.90% and a ROE of 29.28%, highlighting its distinct market position."
      },
      {
        "title": "Is Chromadex Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-chromadex-corp-overvalued-or-undervalued-3634830",
        "imagepath": "",
        "date": "2025-10-20 12:29:36",
        "description": "As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its strong performance metrics, including a P/E ratio of 63, an EV to EBITDA ratio of 58.09, and an impressive ROCE of 1532.90%. \n\nIn comparison to peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, Inc. at 16.23 and LifeVantage Corp. at 14.81, which suggests that while it may seem expensive on a standalone basis, its growth potential is significant. Additionally, the PEG ratio of 0.07 indicates that the stock is undervalued relative to its expected growth. Over the past year, Chromadex has returned 113.08%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned well for future growth despite recent volatility...."
      },
      {
        "title": "Is Chromadex Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-chromadex-corp-overvalued-or-undervalued-3632364",
        "imagepath": "",
        "date": "2025-10-19 12:06:57",
        "description": "As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, particularly when considering its PEG ratio of 0.07, which suggests strong growth potential relative to its price, alongside a high ROCE of 1532.90% and a P/E ratio of 63. \n\nIn comparison to peers, Chromadex Corp. has a P/E of 39.81, which is lower than USANA Health Sciences, Inc. at 16.23 and higher than LifeVantage Corp. at 14.81, indicating a competitive position within the industry. The company's recent stock performance has outpaced the S&P 500, with a 1-year return of 113.08% compared to the index's 14.08%, reinforcing the attractiveness of its current valuation...."
      },
      {
        "title": "Chromadex Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Unique Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/chromadex-corp-sees-valuation-grade-change-from-expensive-to-fair-amid-price-decline-3595345",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ChromadexCorp_valuationdot_3595345.png",
        "date": "2025-10-06 15:46:18",
        "description": "Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $6.93. Over the past year, it achieved a 99.71% return, significantly surpassing the S&P 500. Key metrics include a P/E ratio of 63 and a remarkable ROCE of 1532.90%."
      },
      {
        "title": "Is Chromadex Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-chromadex-corp-technically-bullish-or-bearish-3546927",
        "imagepath": "",
        "date": "2025-09-20 19:43:10",
        "description": "As of 14 July 2025, the technical trend for Chromadex Corp. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD, Bollinger Bands, and OBV are bullish. The daily moving averages indicate a bullish stance. Overall, the mixed signals suggest a mildly bullish outlook. \n\nIn terms of performance, Chromadex has significantly outperformed the S&P 500 over the past year with a return of 185.63% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Chromadex Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-chromadex-corp-overvalued-or-undervalued-3543396",
        "imagepath": "",
        "date": "2025-09-20 18:18:17",
        "description": "As of 6 August 2025, the valuation grade for Chromadex Corp. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 63, a Price to Book Value of 18.43, and an EV to EBITDA ratio of 58.09, all of which are significantly higher than industry norms, suggesting that investors are paying a premium for its shares.\n\nIn comparison to its peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, which stands at 16.23, and LifeVantage Corp., which has a P/E of 14.81, further reinforcing its expensive valuation status. Despite impressive recent returns, such as a 185.63% increase over the past year compared to the S&P 500's 17.14%, the elevated valuation metrics indicate that the stock may not be justified at its current price level...."
      },
      {
        "title": "Chromadex Corp. Emerges as Multibagger with 172.68% Return Over the Past Year",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/chromadex-corp-emerges-as-multibagger-with-17268-return-over-the-past-year-3520026",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/ChromadexCorp_multibagger_3520026.png",
        "date": "2025-09-16 15:18:53",
        "description": "Chromadex Corp. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved impressive returns, significantly outpacing the S&P 500, while demonstrating consistent growth in net sales and profit. With robust operating cash flow and a solid return on capital employed, Chromadex remains a notable player in the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 14,
    "sid": "1152305",
    "stock_news_url": "https://www.marketsmojo.com/news/chromadex-corp-1152305"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Chromadex Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-10-30 15:33:16

Chromadex Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has performed well over the past year, recent trends show a decline. Mixed technical indicators suggest varying momentum, prompting investor attention on the company's market position.

Is Chromadex Corp. overvalued or undervalued?

2025-10-21 12:12:27

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company appears to be undervalued, particularly given its impressive PEG ratio of 0.07, which suggests significant growth potential relative to its price, alongside a high ROCE of 1532.90% and a ROE of 29.28%. In comparison to peers, Chromadex Corp. has a P/E ratio of 63, which is notably higher than LifeVantage Corp.'s attractive P/E of 14.81, yet lower than USANA Health Sciences' expensive P/E of 16.23. Despite recent short-term underperformance, with a 1-month return of -23.88% compared to the S&P 500's 0.96%, the company has shown remarkable long-term performance, with a 1-year return of 113.08% versus the S&P 500's 14.08%. This long-term outperformance reinforces the attractiveness of Chromadex Corp.'s current valuation....

Chromadex Corp. Experiences Valuation Adjustment Amid Strong Financial Performance Indicators

2025-10-20 15:46:37

Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has a notably high P/E ratio of 63 and a Price to Book Value of 18.43. Despite elevated valuation metrics, the company demonstrates strong operational efficiency with a ROCE of 1532.90% and a ROE of 29.28%, highlighting its distinct market position.

Is Chromadex Corp. overvalued or undervalued?

2025-10-20 12:29:36

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its strong performance metrics, including a P/E ratio of 63, an EV to EBITDA ratio of 58.09, and an impressive ROCE of 1532.90%. In comparison to peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, Inc. at 16.23 and LifeVantage Corp. at 14.81, which suggests that while it may seem expensive on a standalone basis, its growth potential is significant. Additionally, the PEG ratio of 0.07 indicates that the stock is undervalued relative to its expected growth. Over the past year, Chromadex has returned 113.08%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned well for future growth despite recent volatility....

Is Chromadex Corp. overvalued or undervalued?

2025-10-19 12:06:57

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, particularly when considering its PEG ratio of 0.07, which suggests strong growth potential relative to its price, alongside a high ROCE of 1532.90% and a P/E ratio of 63. In comparison to peers, Chromadex Corp. has a P/E of 39.81, which is lower than USANA Health Sciences, Inc. at 16.23 and higher than LifeVantage Corp. at 14.81, indicating a competitive position within the industry. The company's recent stock performance has outpaced the S&P 500, with a 1-year return of 113.08% compared to the index's 14.08%, reinforcing the attractiveness of its current valuation....

Chromadex Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Unique Metrics

2025-10-06 15:46:18

Chromadex Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $6.93. Over the past year, it achieved a 99.71% return, significantly surpassing the S&P 500. Key metrics include a P/E ratio of 63 and a remarkable ROCE of 1532.90%.

Is Chromadex Corp. technically bullish or bearish?

2025-09-20 19:43:10

As of 14 July 2025, the technical trend for Chromadex Corp. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD, Bollinger Bands, and OBV are bullish. The daily moving averages indicate a bullish stance. Overall, the mixed signals suggest a mildly bullish outlook. In terms of performance, Chromadex has significantly outperformed the S&P 500 over the past year with a return of 185.63% compared to the S&P 500's 17.14%....

Is Chromadex Corp. overvalued or undervalued?

2025-09-20 18:18:17

As of 6 August 2025, the valuation grade for Chromadex Corp. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 63, a Price to Book Value of 18.43, and an EV to EBITDA ratio of 58.09, all of which are significantly higher than industry norms, suggesting that investors are paying a premium for its shares. In comparison to its peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, which stands at 16.23, and LifeVantage Corp., which has a P/E of 14.81, further reinforcing its expensive valuation status. Despite impressive recent returns, such as a 185.63% increase over the past year compared to the S&P 500's 17.14%, the elevated valuation metrics indicate that the stock may not be justified at its current price level....

Chromadex Corp. Emerges as Multibagger with 172.68% Return Over the Past Year

2025-09-16 15:18:53

Chromadex Corp. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved impressive returns, significantly outpacing the S&P 500, while demonstrating consistent growth in net sales and profit. With robust operating cash flow and a solid return on capital employed, Chromadex remains a notable player in the Pharmaceuticals & Biotechnology sector.

View All News